The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance

BACKGROUND: Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate cancer. However, after several years of ADT, most patients wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ao, Gao, Yi, Wang, Qi, Lin, Wenhao, Ma, Zhiyang, Yang, Xiaoqun, Chen, Lu, Xu, Danfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510184/
https://www.ncbi.nlm.nih.gov/pubmed/37726835
http://dx.doi.org/10.1186/s12967-023-04320-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510184/
https://www.ncbi.nlm.nih.gov/pubmed/37726835
http://dx.doi.org/10.1186/s12967-023-04320-2

Ejemplares similares